BioAge Labs, Inc. BIOA
Set alert
5.87 USD -0.07 -1.18%
At close · Oct 30
5.87 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
5.63 Day range 5.93
4.84 52-week range 25.10
- YTD
- -55.63%
- 1 year
- -24.06%
- Open
- 5.86
- Prev close
- 5.94
- Mkt cap
- 269.41M
- Vol
- 801.36K
- Avg vol
- 964.44K
- EPS
- -2.39
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 5.63
- High
- 5.93
- Forward P/E
- -12.08
- Beta
- 0.00
- Short ratio
- 4.63
- Inst. own
- 85.48%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 18.87
- 200-d avg
- 15.13
- 1y target
- 49.50
1D chart
Signals (25)
| Name | Time | Ago |
|---|---|---|
| RSI: Overbought | 3:58 PM | 2 days ago |
| MACD: Sell Signal | 3:48 PM | 2 days ago |
| RSI: Overbought | 3:40 PM | 2 days ago |
| RSI: Overbought | 3:36 PM | 2 days ago |
| RSI: Overbought | 3:32 PM | 2 days ago |
| RSI: Overbought | 3:26 PM | 2 days ago |
| SMA: Bullish | 3:10 PM | 2 days ago |
| MACD: Buy Signal | 2:39 PM | 2 days ago |
| RSI: Oversold | 2:16 PM | 2 days ago |
| RSI: Oversold | 2:01 PM | 2 days ago |
| SMA: Bearish | 1:55 PM | 2 days ago |
| MACD: Sell Signal | 1:54 PM | 2 days ago |
| RSI: Overbought | 1:44 PM | 2 days ago |
| MACD: Buy Signal | 1:11 PM | 2 days ago |
| MACD: Sell Signal | 12:50 PM | 2 days ago |
| SMA: Bullish | 12:48 PM | 2 days ago |
| SMA: Bearish | 12:46 PM | 2 days ago |
| SMA: Bearish | 12:44 PM | 2 days ago |
| SMA: Bullish | 12:34 PM | 2 days ago |
| SMA: Bullish | 12:31 PM | 2 days ago |
| MACD: Buy Signal | 12:04 PM | 2 days ago |
| SMA: Bearish | 11:31 AM | 2 days ago |
| SMA: Bearish | 11:29 AM | 2 days ago |
| MACD: Sell Signal | 11:21 AM | 2 days ago |
| MACD: Buy Signal | 10:37 AM | 2 days ago |
Key statistics
- Market cap
- 1.11B
- Enterprise value
- 671.26M
- Trailing P/E
- 0.00
- Forward P/E
- -12.08
- PEG ratio
- 0.00
- Price / sales
- 107.25
- Price / book
- 2.91
- EPS (TTM)
- -2.40
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 10.32M
- Revenue growth
- 91.00%
- Free cash flow
- -58.34M
- Total cash
- 383.19M
- Total debt
- 4.03M
- Return on equity
- -25.98%
- Shares outstanding
- 44.45M
- Short % of float
- 5.06%
- 50-day average
- 18.87
- 200-day average
- 15.13
Analyst view
Consensus: none
Price target (mean) 49.50 +743.3% upside
Now 5.87
- Target (low)
- 23.00
- Target (mean)
- 49.50
- Target (high)
- 73.00
Ratings (0m) 9 7 buy · 2 hold · 0 sell
- Strong buy2
- Buy5
- Hold2
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -0.63167.
Financials — quick view
BIOA Revenue — quarterly 2.45M
BIOA Net income — quarterly -26.10M
BIOA EPS — quarterly -0.58
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -0.64142 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.60731 | -0.58 | +0.03 | +4.50% |
| May 8, 2026 | Mar 31, 2026 | -0.63959 | -0.52 | +0.12 | +18.70% |
| Mar 24, 2026 | Dec 31, 2025 | -0.83 | -0.72 | +0.11 | +13.25% |
| Nov 6, 2025 | Sep 30, 2025 | -0.67 | -0.56 | +0.11 | +16.42% |
| Aug 6, 2025 | Jun 30, 2025 | -0.56 | -0.60 | -0.04 | -7.14% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 27, 2026 | Roth Capital | init | — | Buy |
| May 13, 2026 | BTIG | init | — | Buy |
| Mar 27, 2026 | Needham | init | — | Buy |
| Mar 10, 2026 | Citigroup | main | Buy | Buy |
| Feb 25, 2026 | Oppenheimer | init | — | Outperform |
| Feb 18, 2026 | Jefferies | up | Hold | Buy |
About BioAge Labs, Inc.
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- bioagelabs.com
News
- Earnings Preview: BioAge Labs, Inc. (BIOA) Q3 Earnings Expected to Decline
- BioAge Labs (NASDAQ:BIOA) and Royalty Pharma (NASDAQ:RPRX) Critical Comparison
- Deep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First Target
- UBS Initiates Coverage On Bioage Labs with Neutral Rating, Announces Price Target of $8
- Bank of America Corp DE Buys 257,855 Shares of BioAge Labs, Inc. $BIOA
- BioAge Labs to Present at Upcoming Investor Conferences
- 10 Health Care Stocks With Whale Alerts In Today’s Session
- BioAge Labs, Inc. (BIOA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- BioAge Labs, Inc. (BIOA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
- BioAge Labs Doses First Patient In Its Phsae 2 Study Of BGE-102 To Treat Diabetic Macular Edema
Your note
Sign in to keep a note on BIOA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARTON SHANE | Officer | Sale | Jun 29, 2026 | 0 |
| CORMORANT ASSET MANAGEMENT ,L.P | Unknown | Purchase | Sep 26, 2024 | 0 |
| ENRIGHT PATRICK G. | Director | Purchase | Sep 26, 2024 | 0 |
| FORTNEY KRISTEN | Chief Executive Officer | Sale | Jan 12, 2026 | 976,949 |
| GOLDSTEIN DOV A | Chief Financial Officer | Conversion of Exercise of derivative security | Apr 22, 2026 | 36,575 |
| HEALY JAMES I | Director | Purchase | Sep 26, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| a16z Capital Management, L.L.C. | 7.27% | 3,233,170 | 80.47M | Mar 30, 2026 |
| Cormorant Asset Management, LP | 6.50% | 2,890,605 | 71.95M | Mar 30, 2026 |
| Sofinnova Investments, Inc. | 5.16% | 2,293,788 | 57.09M | Mar 30, 2026 |
| Blackrock Inc. | 5.10% | 2,267,756 | 56.44M | Mar 30, 2026 |
| Janus Henderson Group PLC | 4.71% | 2,094,270 | 52.13M | Mar 30, 2026 |
| Octagon Capital Advisors LP | 3.93% | 1,748,000 | 43.51M | Mar 30, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.22% | 985,493 | 24.53M | Mar 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.63% | 725,323 | 18.05M | May 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.76% | 336,229 | 8.37M | Mar 30, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.67% | 298,933 | 7.44M | Apr 29, 2026 |
| iShares Trust-iShares Russell 2000 Value ETF | 0.60% | 264,819 | 6.59M | May 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Pharmaceuticals ETF | 0.51% | 228,473 | 5.69M | May 30, 2026 |